Correlation Between Oxford Cannabinoid and PsyBio Therapeutics

Can any of the company-specific risk be diversified away by investing in both Oxford Cannabinoid and PsyBio Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oxford Cannabinoid and PsyBio Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Oxford Cannabinoid Technologies and PsyBio Therapeutics Corp, you can compare the effects of market volatilities on Oxford Cannabinoid and PsyBio Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oxford Cannabinoid with a short position of PsyBio Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oxford Cannabinoid and PsyBio Therapeutics.

Diversification Opportunities for Oxford Cannabinoid and PsyBio Therapeutics

0.0

Correlation Coefficient

Oxford Cannabinoid  PsyBio Therapeutics

Pay attention - limited upside

The 3 months correlation between Oxford and PsyBio is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Oxford Cannabinoid Technologie and PsyBio Therapeutics Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on PsyBio Therapeutics Corp and Oxford Cannabinoid is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oxford Cannabinoid Technologies are associated (or correlated) with PsyBio Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of PsyBio Therapeutics Corp has no effect on the direction of Oxford Cannabinoid i.e., Oxford Cannabinoid and PsyBio Therapeutics go up and down completely randomly.

Pair Corralation between Oxford Cannabinoid and PsyBio Therapeutics

Assuming the 90 days horizon Oxford Cannabinoid is expected to generate 1.59 times less return on investment than PsyBio Therapeutics. But when comparing it to its historical volatility, Oxford Cannabinoid Technologies is 1.37 times less risky than PsyBio Therapeutics. It trades about 0.06 of its potential returns per unit of risk. PsyBio Therapeutics Corp is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  0.52  in PsyBio Therapeutics Corp on October 5, 2024 and sell it today you would lose (0.51) from holding PsyBio Therapeutics Corp or give up 98.08% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	99.6%
Values	Daily Returns

Oxford Cannabinoid Technologie  vs.  PsyBio Therapeutics Corp

Oxford Cannabinoid

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Oxford Cannabinoid Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable technical indicators, Oxford Cannabinoid is not utilizing all of its potentials. The newest stock price disturbance, may contribute to mid-run losses for the stockholders.

PsyBio Therapeutics Corp

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in PsyBio Therapeutics Corp are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile fundamental drivers, PsyBio Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Oxford Cannabinoid and PsyBio Therapeutics

The main advantage of trading using opposite Oxford Cannabinoid and PsyBio Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oxford Cannabinoid position performs unexpectedly, PsyBio Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PsyBio Therapeutics will offset losses from the drop in PsyBio Therapeutics' long position.

The idea behind Oxford Cannabinoid Technologies and PsyBio Therapeutics Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.